Zinexts Expands Neurodegenerative Disease Testing Capabilities with Automated APOE Multiplex Gene Test

As Taiwan continues to advance integrated neurological care and smart medical technologies[1], Zinexts is expanding its molecular diagnostics portfolio into one of today’s most challenging areas of healthcare: neurodegenerative diseases.

Zinexts proudly supports Taiwan’s development of advanced neurology care through its fully automated sample-to-result solution, NeXgen™ 16HP, and the newly developed APOE genotyping qPCR assay. The APOE gene is widely recognized as a crucial genetic factor associated with Alzheimer’s disease risk.
The NeXgen™ 16HP system has been trusted by one of Taiwan’s key medical institutions, Taipei Medical University (TMU), to support APOE gene testing for Alzheimer’s-related applications.

Within TMU’s cross-hospital neurology network, which includes Shuang Ho Hospital’s Central Laboratory for Precision Medicine , Zinexts’ automated APOE testing solution provides high-quality target detection to identify the key genetic biomarkers relevant to more personalized approaches to neurodegenerative disease assessment.

To further strengthen its role in neurodegenerative care and preventive diagnostics, Zinexts has partnered with JW Diagnostics Inc., a subsidiary of Bio-Check Laboratories Ltd., With established experience in precision diagnostics, JW Diagnostics Inc. adds complementary rare disease biomarker insights that support a more integrated approach to Alzheimer’s-related testing and beyond.

By combining NeXgen™ 16HP sample-to-result automation, APOE gene testing, and biomarker-based insights, Zinexts supports a strong integrated approach to precision medicine for neurodegenerative diseases.
 
Reference
[1] JAMA Network Open. 2026;9(3):e260853. doi:10.1001/jamanetworkopen.2026.0853